Press Releases

Nextech3D.ai Continues to Sign New & Renewal 3D Modeling Deals plus AR Visualization For Enterprise Ecommerce

TORONTO, ON / ACCESSWIRE / May 17, 2024 / Nextech3D.AI (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a patented 2D-3D generative AI-powered 3D model supplier (Patent #11,948,248) for major e-commerce retailers including Amazon, Miele, P&G, and Kohl's, is pleased to announce a series of exciting new deals and renewals for its 3D modeling business. To date, the company has... (continue reading...)

TORONTO, ON / ACCESSWIRE / May 17, 2024 / ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB: ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce two new deals with new partners;

Ershad Technologies & IOTrackers - https://iotrackers.com/

• Upgraded from Developer to Partner Account after successfully... (continue reading...)

Marijuana and alcohol remain the most detected drugs in impaired driving incidents leading to serious or fatal injuries

WASHINGTON, May 17, 2024 /PRNewswire/ -- The American Trucking Associations is calling attention to the negative consequences for highway safety and safety-sensitive industries that could result from the U.S. Drug Enforcement Administration's proposal to reschedule marijuana from a Schedule I to a Schedule III drug. In anticipation of the proposed... (continue reading...)

SANTA CLARA, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Applied Materials, Inc. today announced that Gary Dickerson, President and CEO, and Brice Hill, Senior Vice President and CFO, will participate in fireside chats at upcoming investor conferences.

Mr. Dickerson will participate at the Bernstein Strategic Decisions Conference in New York on Thursday, May 30 beginning at 11:30 a.m. PT / 2:30 p.m. ET.

Mr. Hill will participate at the BofA Securities Global Technology... (continue reading...)

-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)-    Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers -   ... (continue reading...)